Having trouble accessing articles? Reset your cache.

Arch's golden returns

Tallying Arch Venture's wins from Agios and Receptos

Mid-month SEC filings show Arch Venture Partners has used two companies with roaring stock prices - Agios Pharmaceuticals Inc. (NASDAQ:AGIO) and Receptos Inc. (NASDAQ:RCPT) - to completely pay back LPs in its $400 million seventh fund. A potentially

Read the full 389 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers